NFYB

Across TCGA pan-cancer cohorts, NFYB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NFYB data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NFYB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NFYB expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where NFYB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.765	0.484	<.001	43	view →
CCRCC	OS	Median	All	0.933	0.756	.005	21	view →
PDAC	OS	Tertile	II,III,IV	0.938	0.667	.031	5	view →
HNSC	DFS	Quartile	III,IV	1.000	0.891	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NFYB–LUAD (DFS)

Open the LUAD breakdown →